Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weijing Sun

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
Cells|September 28, 2023
Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) PatientsIan M Freed, Anup Kasi, Oluwadamilola Fateru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2016
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometryJames J Lee, Jabed Seraj, Kenichiro Yoshida, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairmentMuhammad Wasif Saif, Carlos R Becerra, Marwan G Fakih, et al.
Nature Communications|July 2, 2025
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Shurui Zhou, Xiaoqing Xu, et al.
Cancer Research|January 25, 2019
Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic ResponsePrabhu Ramamoorthy, Sufi Mary Thomas, Gaurav Kaushik, et al.
Nature Communications|February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohortAnwaar Saeed, Robin Park, Harsh Pathak, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
Cells|September 28, 2023
Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) PatientsIan M Freed, Anup Kasi, Oluwadamilola Fateru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2016
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometryJames J Lee, Jabed Seraj, Kenichiro Yoshida, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairmentMuhammad Wasif Saif, Carlos R Becerra, Marwan G Fakih, et al.
Nature Communications|July 2, 2025
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Shurui Zhou, Xiaoqing Xu, et al.
Cancer Research|January 25, 2019
Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic ResponsePrabhu Ramamoorthy, Sufi Mary Thomas, Gaurav Kaushik, et al.
Nature Communications|February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohortAnwaar Saeed, Robin Park, Harsh Pathak, et al.
Pageof 14